Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Claire GalloisQian ShiJeffrey P MeyersTimothy J IvesonSteven R AlbertsAimery deGramontAlberto F SobreroDaniel G HallerEiji OkiAnthony Frank ShieldsRichard M GoldbergRachel KerrSara LonardiGreg YothersCaroline KellyIoannis BoukovinasRoberto LabiancaFrank A SinicropeIoannis SouglakosTakayuki YoshinoJeffrey A MeyerhardtThierry AndréDemetris PapamichaelGilles ManceauPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In patients treated with 6 months of oxaliplatin-based chemotherapy for stage III CC, ETD was associated with poorer oncologic outcomes. However, this was not the case for EOD. These data favor discontinuing oxaliplatin while continuing fluoropyrimidine in individuals with significant neurotoxicity having received > 50% of the planned 6-month chemotherapy.